Adjunctive treatment with pioglitazone did not produce a statistically significant improvement in cognitive performance over a twelve-month study period in adults with clinically diagnosed dementia and cognitive impairment of unconfirmed etiology. Findings from the prospective, double-blind randomized controlled trial revealed that adding the medication to standard background donepezil therapy failed to demonstrate significant cognitive or electrophysiological benefits compared with placebo.
The study rationale was grounded in evidence implicating insulin resistance and impaired cerebral energy metabolism in cognitive dysfunction. Researchers sought to evaluate pioglitazone as a potentially transdiagnostic metabolic intervention. Because cognitive impairment can stem from neurodegenerative, vascular, metabolic, and other origins, the clinical investigation was designed to assess treatment responses broadly across adults with clinically diagnosed dementia rather than serving as an Alzheimer’s disease-specific intervention.
Conducted as a single-centre trial, the study enrolled 113 adults between the ages of 18 and 64 years who presented with clinically diagnosed dementia and cognitive impairment, defined by a Montreal Cognitive Assessment score of less than 26. Dementia diagnoses were established clinically by the study neurologist in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria, without requiring biomarker confirmation of underlying pathology.
Participants were randomly assigned to receive either pioglitazone at an oral dose of 15 mg once daily combined with background donepezil therapy or an identical placebo regimen combined with background donepezil therapy. The assigned pharmacological interventions were administered during the initial six months of the protocol, which was immediately succeeded by an additional six-month post-treatment observation period, bringing the total evaluation period to twelve months.
Primary efficacy endpoints included longitudinal changes in Montreal Cognitive Assessment scores, P300 event-related potential latency, P300 amplitude, and the plasma amyloid-beta 42 to amyloid-beta 40 ratio. Mixed-model repeated-measures analysis indicated no statistically significant between-group differences across any primary measures, with Montreal Cognitive Assessment scores yielding a P-value of 0.07, P300 latency at P = 0.300, P300 amplitude at P = 0.71, and the plasma amyloid ratio at P = 1.00.
Secondary outcomes assessed safety profiles and participant quality of life throughout the trial duration. Investigators documented a total of 32 adverse drug reactions during the study. Specifically, 17 participants, representing 34.0 percent of the intervention cohort, and 15 participants, representing 30.6 percent of the control cohort, reported at least one adverse drug reaction, demonstrating no statistically significant overall difference between groups (P = 0.82).
The study authors emphasized critical diagnostic limitations when contextualizing the neutral outcomes. Because Alzheimer’s disease pathology was not verified through central biomarkers or validated blood-based biomarkers, these results cannot be interpreted as evidence either for or against potential disease-modifying effects of pioglitazone in Alzheimer’s disease specifically, remaining limited to clinically defined dementia of unconfirmed origin.
Beyond general cognitive performance, mixed-model repeated-measures analysis confirmed that adjunctive pioglitazone did not produce detectable between-group changes in electrophysiological or exploratory plasma amyloid measures. The electrophysiological evaluations examined P300 event-related potential latency and amplitude, while exploratory plasma measures assessed the amyloid ratio.
The trial was formally registered under clinical trial number CTRI2024/09/074281 on September 24, 2024.
Subject of Research: Adjunctive pioglitazone efficacy in clinically diagnosed dementia
Article Title: Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial
Article References: Osoro, I., Wilson, R. S., & Rajanandh, M. G. (2026). Efficacy of pioglitazone in improving cognitive function among dementia patients- a prospective, double blind randomized controlled trial. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-026-03556-4
Image Credits: AI Generated
DOI: 10.1007/s40520-026-03556-4
Keywords: pioglitazone, dementia, cognitive impairment, Montreal Cognitive Assessment, donepezil, P300 latency, P300 amplitude, event-related potentials, plasma amyloid, Aβ42/Aβ40 ratio, randomized controlled trial, insulin resistance, cerebral metabolism, DSM-5 criteria, adverse drug reactions, double-blind trial
News Source: Cassandra Pierce. (November 19, 2026). Trial Finds Adjunctive Pioglitazone Does Not Improve Cognitive Function in Dementia. Scienmag.



